Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial

被引：0
|
作者：
Siegel, David Samuel DiCapua
Richardson, Paul Gerard Guy
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid C.
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej J.
Bahlis, Nizar J.
Song, Kevin W.
Belch, Andrew
Raje, Noopur S.
Shustik, Chaim
Lentzsch, Suzanne
Chen, Min
Zaki, Mohamed H.
Anderson, Kenneth Carl
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Washington Univ, St Louis, MO USA
[4] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[6] Mt Sinai Med Ctr, New York, NY 10029 USA
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[8] Emory Univ, Sch Med, Atlanta, GA USA
[9] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[10] Univ Calgary, Calgary, AB, Canada
[11] Vancouver Gen Hosp, Vancouver, BC, Canada
[12] Univ Alberta, Edmonton, AB, Canada
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
[14] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada
[15] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[16] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8588
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Attal, Michel
    Rajkumar, S. Vincent
    San Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey S. Y.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Corzo, Kathryn Penkus
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
    Dimopoulos, Meletios
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ardizzoia, Antonio
    Kueenburg, Elisabeth
    Collins, Shona
    Di Micco, Antonia
    Rosettani, Barbara
    Li, Yan
    Bacon, Pamela
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +
  • [43] A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)
    Niederwieser, Dietger
    Richardson, Paul
    Attal, Michel
    Rajkumar, Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulosu, Meletios
    Huan, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Mace, Sandrine
    Prince, H. Miles
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 40 - 41
  • [44] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)
    Qian, Xiaozhong
    Newhall, Kathryn
    Tometsko, Mark
    Bjorklund, Chad
    Ma, Jianglin
    Bahlis, Nizar J.
    Siegel, David
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin W.
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanthi
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Mouro, Jorge
    Agarwal, Amit
    Zafar, Faiza
    Thakurta, Anjan
    BLOOD, 2017, 130
  • [45] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Fu, Wei-Jun
    Wang, Ya-Fei
    Zhao, Hong-Guo
    Niu, Ting
    Fang, Bai-Jun
    Liao, Ai-Jun
    Bai, Hai
    Lu, Jin
    BMC CANCER, 2022, 22 (01)
  • [46] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Wei-Jun Fu
    Ya-Fei Wang
    Hong-Guo Zhao
    Ting Niu
    Bai-Jun Fang
    Ai-Jun Liao
    Hai Bai
    Jin Lu
    BMC Cancer, 22
  • [47] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
    San Miguel, Jesus F.
    Weisel, Katja
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Martinez-Lopez, Joaquin
    Chen, Christine I.
    Renner, Christoph
    Bahlis, Nizar J.
    Yu, Xin
    Teasdale, Terri
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    BLOOD, 2013, 122 (21)
  • [48] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for Res crossover.
    Morgan, Gareth J.
    San Miguel, Jesus
    Dhanasiri, Sujith
    Lee, Dawn
    Palumbo, Antonio
    Facon, Thierry
    Zaki, Mohamed H.
    Yu, Xin
    Sternas, Lars Axel
    Jacques, Christian
    Weisel, Katja C.
    Offner, Fritz
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Safety and Efficacy of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN) Based Treatment (Tx) Failure
    Siegel, David
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin W.
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanthi
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Mouro, Jorge
    Agarwal, Amit
    Zafar, Faiza
    Qian, Max
    Thakurta, Anjan
    Bahlis, Nizar J.
    BLOOD, 2017, 130
  • [50] A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
    Hagiwara, S.
    Okamoto, S.
    Matsue, K.
    Iida, S.
    Sunami, K.
    Komeno, T.
    Suzuki, K.
    Ando, K.
    Taniwaki, M.
    Tobinai, K.
    Chou, T.
    Kaneko, H.
    Iwasaki, H.
    Uemura, C.
    Tamakoshi, H.
    Zaki, M. H.
    Doerr, T.
    Kuroda, Y.
    Ichinohe, T.
    HAEMATOLOGICA, 2016, 101 : 790 - 790
12345